Current Opinion in Oncology最新文献_第5页

Aspirin for colorectal cancer chemoprevention: where are we? 阿司匹林用于结直肠癌化学预防：进展如何？

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-07-01 Epub Date: 2025-05-16 DOI: 10.1097/CCO.0000000000001153

Vassilis Genoud, Floryane Kim, Thibaud Koessler

{"title":"Aspirin for colorectal cancer chemoprevention: where are we?","authors":"Vassilis Genoud, Floryane Kim, Thibaud Koessler","doi":"10.1097/CCO.0000000000001153","DOIUrl":"10.1097/CCO.0000000000001153","url":null,"abstract":"Purpose of review: Aspirin (acetylsalicylic acid, ASA) is gaining recognition as a possible chemopreventive agent for colorectal cancer (CRC). This review explores current evidence on ASA use in both primary and secondary prevention of CRC among sporadic cases and in patients with Lynch syndrome (LS).Recent findings: Observational cohorts consistently indicate a modest, time-dependent reduction in CRC incidence with long-term ASA use, especially in individuals with elevated baseline risk. In LS, extended follow-up from randomized trials reveals a robust protective effect, although the ideal dose remains unsettled. For secondary prevention, randomized trials in unselected patients did not detect a clear advantage, on the other hand tumors harboring Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA)-mutation have a substantial gains in recurrence prevention, emphasizing the role of molecular stratification.Summary: Accumulating evidence supports a nuanced approach to ASA chemoprevention, tailoring treatment to each patient's genetic background, lifestyle factors, and risk profile. Ongoing research on dosage optimization and biomarker-driven selection is expected to further refine the integration of ASA into standard CRC prevention strategies.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"383-390"},"PeriodicalIF":2.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Burnout among health professionals working in oncology: current evidence and challenges for future research. 肿瘤学卫生专业人员的职业倦怠：当前证据和未来研究的挑战。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-07-01 Epub Date: 2025-02-13 DOI: 10.1097/CCO.0000000000001132

Javier Martinez-Calderon, Cristina García-Muñoz

{"title":"Burnout among health professionals working in oncology: current evidence and challenges for future research.","authors":"Javier Martinez-Calderon, Cristina García-Muñoz","doi":"10.1097/CCO.0000000000001132","DOIUrl":"10.1097/CCO.0000000000001132","url":null,"abstract":"Purpose of review: This review aims to show the current evidence and the challenges that remain to guide future research on the prevalence, incidence, prognosis, and factors associated with burnout, and current interventions for its prevention and reduction.Recent findings: An overview of systematic reviews with meta-analyses found that burnout is highly prevalent among oncologists and oncology nurses, mainly emotional exhaustion. However, these meta-analyses showed a lack of original research from continents such as Africa or Oceania, and no studies were meta-analyzed evaluating physical therapists or psycho-oncologists. To our knowledge, the incidence of occupational burnout has not been meta-analyzed on this topic, and the number of prospective cohort studies and randomized clinical trials is probably limited. On the other hand, some cross-sectional studies and nonrandomized clinical trials have been recently published. These studies have highlighted the association between burnout with psychological (e.g. anxiety) and occupational factors (e.g. job demands) and the reduction of burnout using different psychological interventions.Summary: Occupational burnout is a topic of interest in oncology. However, important gaps in knowledge remain and need to be filled before establishing firm conclusions on this topic.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"302-306"},"PeriodicalIF":2.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Next questions on gastrointestinal stromal tumors: unresolved challenges and future directions. 胃肠道间质瘤的下一个问题：未解决的挑战和未来的方向。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-07-01 Epub Date: 2025-04-04 DOI: 10.1097/CCO.0000000000001145

Davide Romandini, Pawel Sobczuk, Carlo M Cicala, César Serrano

{"title":"Next questions on gastrointestinal stromal tumors: unresolved challenges and future directions.","authors":"Davide Romandini, Pawel Sobczuk, Carlo M Cicala, César Serrano","doi":"10.1097/CCO.0000000000001145","DOIUrl":"10.1097/CCO.0000000000001145","url":null,"abstract":"Purpose of review: Despite remarkable progress in the management of gastrointestinal stromal tumors (GISTs), critical challenges persist. Key aspects such as risk stratification, the optimal duration of adjuvant therapy, and strategies to enhance the efficacy of first-line treatment remain subjects of ongoing debate. This review explores emerging concepts and innovative approaches aimed at refining patient selection and optimizing therapeutic decision-making to further improve clinical outcomes.Recent findings: Molecular and genomic parameters have the potential to enhance traditional risk models, enabling more precise stratification of high-risk patients. Innovations in artificial intelligence and liquid biopsy are emerging as powerful tools for refining predictions of recurrence and treatment response. Meanwhile, the definition and prognostic significance of tumor rupture remain pivotal challenges that influence both risk assessment and adjuvant therapy decisions. Furthermore, transcriptomic and multiomic analyses have unveiled distinct GIST subtypes with significant prognostic and therapeutic implications, paving the way for more tailored treatment strategies.Summary: Integrating molecular features into clinical decision making may refine risk assessment and personalize the treatment in patients with GIST. Future research should focus on validating these tools and redefine clinical trial designs to accelerate drug development for this rare disease.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"358-364"},"PeriodicalIF":2.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Maintenance therapy for pediatric sarcoma: full throttle ahead? 儿童肉瘤的维持治疗：全速前进？

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-07-01 Epub Date: 2025-04-21 DOI: 10.1097/CCO.0000000000001148

Nadège Corradini, Nicolas André, Daniel Orbach

{"title":"Maintenance therapy for pediatric sarcoma: full throttle ahead?","authors":"Nadège Corradini, Nicolas André, Daniel Orbach","doi":"10.1097/CCO.0000000000001148","DOIUrl":"10.1097/CCO.0000000000001148","url":null,"abstract":"Purpose of review: Maintenance therapy (MT), particularly antiangiogenic approaches such metronomic chemotherapy (MC), correspond to the continuous administration of low-dose anticancer agents in a context of minimal residual disease. While widely used in pediatric acute lymphoblastic leukemia for decades, MT has recently shown promise in solid tumors. Additionally, antivascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) are increasingly explored in pediatric sarcomas.Recent findings: This review summarize current evidence on MT efficacy in pediatric sarcomas, focusing on MC and TKIs. It examines their impact on the tumor microenvironment and cancer progression, as well as potential future applications, including standalone use or combination with targeted therapies, immunotherapies and/or drug repurposing.Summary: MT has been demonstrated to improve outcomes in specific sarcomas, especially high-risk localized rhabdomyosarcoma, and has therefore become a standard of care. Its role in other sarcomas, such as Ewing sarcoma and osteosarcoma, is under investigation. However, critical challenges remain, including optimizing drug selection, treatment duration, and patient stratification to maximize benefits.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"347-357"},"PeriodicalIF":2.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing proactive life-sustaining treatment preference documentation in advanced cancer care: barriers and recommendations. 加强晚期癌症护理中主动维持生命的治疗偏好文件：障碍和建议。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-07-01 Epub Date: 2025-04-02 DOI: 10.1097/CCO.0000000000001144

Lisa Choucroun, Pierre Gérain

{"title":"Enhancing proactive life-sustaining treatment preference documentation in advanced cancer care: barriers and recommendations.","authors":"Lisa Choucroun, Pierre Gérain","doi":"10.1097/CCO.0000000000001144","DOIUrl":"10.1097/CCO.0000000000001144","url":null,"abstract":"Purpose of review: Despite guidelines, life-sustaining treatment preferences (LSTP) documentation for advanced cancer patients remains limited and reactive to clinical events. As proactive documentation is a core component of early palliative care (EPC), addressing barriers to EPC can in parallel facilitate LSTP documentation. This narrative review examines barriers to both processes and proposes recommendations to overcome them.Recent findings: Barriers stem from patients, oncologists, and the healthcare system. Patients and oncologists face communication challenges. For patients, knowledge gaps on illness and LSTP documentation, family dynamics prioritizing informal over formal discussions, and limited intercultural considerations, compound these challenges. For oncologists, a curative-focused medical culture reinforces them. In the healthcare system, this culture contributes to deprioritizing LSTP documentation.Summary: Addressing these barriers requires multilevel recommendations. For patients: interventions to enhance illness understanding, foster culturally sensitive oncologist communication, and optimize care organization. For oncologists: integrating communication training and palliative care (PC) knowledge into oncology fellowships while cultivating a supportive medical culture for LSTP documentation through role modeling and intervision. For healthcare systems: LSTP documentation benchmarks, proactive EPC integration through automated reminders, telehealth, standardized medical records, and reimbursement codes. Assessing the implementation and sustainability of these recommendations is crucial to enhancing proactive LSTP documentation in advanced cancer care.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"290-301"},"PeriodicalIF":2.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cellular therapies in sarcoma and other solid tumors. 肉瘤和其他实体瘤的细胞疗法。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-07-01 Epub Date: 2025-05-05 DOI: 10.1097/CCO.0000000000001152

Margaux Dupont, Axel de Bernardi, Hélène Vanacker, Armelle Dufresne, Mehdi Brahmi, Jean-Yves Blay

{"title":"Cellular therapies in sarcoma and other solid tumors.","authors":"Margaux Dupont, Axel de Bernardi, Hélène Vanacker, Armelle Dufresne, Mehdi Brahmi, Jean-Yves Blay","doi":"10.1097/CCO.0000000000001152","DOIUrl":"10.1097/CCO.0000000000001152","url":null,"abstract":"Purpose of review: While adoptive cell therapies such as chimeric antigen receptor T (CAR-T) cell have demonstrated efficacy in hematological malignancies, their success in solid tumors remains challenging due to tumor heterogeneity, antigen specificity, and the suppressive tumor microenvironment. This review aims to provide an overview of recent advancements in cellular therapies, in sarcomas and other solid malignancies.Recent findings: In the field of sarcomas, the approval of afamitresgene autoleucel (afami-cel) for synovial sarcoma in Atoxiciugust 2024 marks a milestone in T cell therapy, demonstrating an objective response rate (ORR) of 39% and a median overall survival (OS) of 16.9 months in the SPEARHEAD-1 phase 2 trial. Other trials exploring NY-ESO-1 specific T-cell receptor-engineered T (TCR-T) therapies in myxoid round-cell liposarcoma (MRCL) have shown promising response rates. Beyond sarcomas, CAR-T therapies targeting CLDN18.2 in gastrointestinal cancers, GD2 in gliomas, and PSCA in prostate cancer have demonstrated varying degrees of efficacy, with ongoing research to date.Summary: Clinically, these therapies highlight the need for improved patient selection criteria, and optimized antigen targeting. Toxicity management must also be taken into account, as cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) can be severe. Further studies should focus on improving safety and T cell persistence, and refining manufacturing processes to increase accessibility and scalability.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"365-371"},"PeriodicalIF":2.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Collecting information from all sarcoma reference cancer centres worldwide: achievement and next steps. 从全球所有肉瘤参考癌症中心收集信息：成就和下一步。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-07-01 Epub Date: 2025-04-03 DOI: 10.1097/CCO.0000000000001143

Paolo Lasalvia, Roberto Lillini, Annalisa Trama

{"title":"Collecting information from all sarcoma reference cancer centres worldwide: achievement and next steps.","authors":"Paolo Lasalvia, Roberto Lillini, Annalisa Trama","doi":"10.1097/CCO.0000000000001143","DOIUrl":"10.1097/CCO.0000000000001143","url":null,"abstract":"Purpose of review: Sarcomas are a rare and heterogeneous group of tumours, making large-scale data collection crucial for research and ultimately improve patient outcomes. This review highlights recent initiatives in sarcoma data collection through national and international networks, emphasizing results derived from collaborative efforts. Given the increasing availability of electronic medical data, this review is timely assessing the readiness of sarcoma collaborative datasets to exploit innovation and increase sustainability in the long-term as well as international collaboration.Recent findings: Through a systematic review we identified 8 major sarcoma databases (6 national; 2 international). These initiatives all enhanced prognostication and personalized medicine by also integrating clinical and genomic datasets, while increasing data standardization which is the basis for data interoperability and integration across reference centres. Notable efforts, such as the IDEA4RC project, are establishing interoperable data models using sarcoma as use case to enhance global research.Summary: Collaborative data collection is essential when studying sarcomas. Strengthening international networks will generate real world data networks, increase research and its efficiency, and ultimately ameliorate patient care. Future efforts should focus on expanding data-sharing frameworks, implement innovative solutions for ensuring data interoperability and increase value of real-world evidence in research and therapeutic advancements.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"339-346"},"PeriodicalIF":2.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Which sarcoma requires PD1/PDL1 inhibitors, and what should be the best scheme? Present status and next steps. 哪种肉瘤需要PD1/PDL1抑制剂，最好的方案是什么？当前状态和下一步。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-07-01 Epub Date: 2025-04-21 DOI: 10.1097/CCO.0000000000001149

Javier Martin-Broto, David S Moura, Nadia Hindi

{"title":"Which sarcoma requires PD1/PDL1 inhibitors, and what should be the best scheme? Present status and next steps.","authors":"Javier Martin-Broto, David S Moura, Nadia Hindi","doi":"10.1097/CCO.0000000000001149","DOIUrl":"10.1097/CCO.0000000000001149","url":null,"abstract":"Purpose of review: The introduction of immune checkpoint inhibitors (ICI) in advanced sarcoma has been largely disappointing due to their \"cold\" tumor microenvironment, characterized by low tumor mutational burden, scarce CD8 + T-cell infiltration, and minimal expression of PD-1/PD-L1. However, recent findings highlight several scenarios in which immune checkpoint blockade exhibits clinical efficacy.Recent findings: ICIs have shown durable efficacy in specific sarcoma subtypes, such as alveolar soft part sarcoma (ASPS), with objective response rates (ORR) exceeding 35% and 50%, in monotherapy or in combination, respectively. Doxorubicin-based regimens plus ICIs have yielded notorious and higher ORRs in the most common sarcoma subtypes, than historical chemotherapy data. Neoadjuvant radiation therapy combined with ICIs has significantly improved disease-free survival in localized selected soft tissue sarcomas.Summary: Immunotherapy targeting immune checkpoints in sarcomas is evolving, with recent findings highlighting its potential. Single-arm trials underscore the efficacy of ICIs in rare sarcomas, exemplified by the FDA approval of atezolizumab for ASPS. Combination strategies are proving more effective than chemotherapy alone, with ongoing comparative studies assessing chemo-immunotherapy in both metastatic and localized sarcomas. Advances in predictive biomarkers could expand the clinical use of ICIs.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"331-338"},"PeriodicalIF":2.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial introductions. 编辑介绍。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-04-03 DOI: 10.1097/CCO.0000000000001140

引用次数: 0

The role of biomarkers in the management of HPV-related oropharyngeal cancer. 生物标志物在hpv相关口咽癌治疗中的作用

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-02-05 DOI: 10.1097/CCO.0000000000001126

Benjamin D Hopkins, James E Bates

{"title":"The role of biomarkers in the management of HPV-related oropharyngeal cancer.","authors":"Benjamin D Hopkins, James E Bates","doi":"10.1097/CCO.0000000000001126","DOIUrl":"10.1097/CCO.0000000000001126","url":null,"abstract":"Purpose of review: Patients with HPV-related oropharyngeal cancer have very good survival outcomes but a high burden of toxicity. This has led to significant efforts to attempt to use a variety of biomarkers to select patients who are candidates for de-escalated treatment.Recent findings: Initially, the field used HPV status alone as a biomarker to select patients with oropharyngeal cancer for de-escalation, however, the recently presented results of NRG Oncology HN005 showed that this is an insufficient strategy to select patients for potential de-escalation as patients in that study who received 60 Gy rather than the standard 70 Gy of radiation had diminished progression-free survival. This has led to a myriad of other strategies to potentially identify patients who may be able to receive less intense treatment but maintain a high rate of cure.Summary: Many biomarker options exist to try and select patients for potential treatment de-escalation. We anxiously await the results of multiple ongoing phase II studies regarding many of these biomarkers and believe that the future of treatment for oropharyngeal cancer will be significantly more personalized.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"203-208"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0